Who is sponsoring NCT03204695?

NCT03204695 is sponsored by Coherex Medical.

What drugs are being tested in NCT03204695?

Interventions in NCT03204695: Percutaneous LAA Closure, Anticoagulation or Clopidogrel.

What condition does NCT03204695 study?

NCT03204695 studies Non-valvular Atrial Fibrillation.

Is NCT03204695 still recruiting?

NCT03204695 is currently terminated. Last updated 23 April 2024.

Are results published for NCT03204695?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2024-04-23 · How we verify

NCT03204695

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

WAVECREST Post Market Clinical Follow-Up (PMCF) Study

Terminated NA Results posted Last updated 23 April 2024

What this trial tests

NA trial testing Percutaneous LAA Closure in Non-valvular Atrial Fibrillation in 27 participants. Terminated before completion.

Timeline

29 May 2017

Primary endpoint
14 June 2018

14 June 2018

Quick facts

Lead sponsor	Coherex Medical
Phase	NA
Status	Terminated
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	prevention
Enrollment	27
Start date	29 May 2017
Primary completion	14 June 2018
Estimated completion	14 June 2018
Sites	1 location across Belgium

Drugs / interventions tested

Percutaneous LAA Closure
Anticoagulation or Clopidogrel — full drug profile →

Conditions studied

Non-valvular Atrial Fibrillation — all drugs for Non-valvular Atrial Fibrillation →

Sponsor

Coherex Medical — full company profile →

Who can join

18 and older, any sex, with Non-valvular Atrial Fibrillation. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The WAVECREST PMCF Study is a prospective, non-randomized, multicenter study to confirm safety and performance of the Coherex WaveCrest Left Atrial Appendage (LAA) Occlusion System in the current medical practice setting in patients with non-valvular atrial fibrillation who are at increased risk for stroke. Up to 65 subjects may be enrolled at up to 15 study sites in Europe. Patients will be followed through 45 days post-procedure.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Non-valvular Atrial Fibrillation

Currently open trials in the same condition.

NCT05565599 — An Early Feasibility Study Evaluating the Safety and Efficacy of the Laminar Left Atrial Appendage Closure System in Sub · NA · active not recruiting

Other Coherex Medical trials

Trials by the same sponsor.

NCT03302494 — WAveCrest Vs. Watchman TranssEptal LAA Closure to REduce AF-Mediated STroke 2 · Phase 3 · terminated
NCT01280578 — The Coherex FlatStent™ EF PFO Migraine Registry · terminated

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03204695 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Coherex Medical
Last refreshed: 23 April 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03204695.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing